SIRPA and neoplasm: We sought to 1) profile immune signaling and 2) interrogate potential mechanisms of ICI-related kidney injury in a Human Immune System (HIS) tumor-bearing mouse model treated with nivolumab and ipilimumab.<h4>Methods</h4>Immunodeficient BRGS (BALB/c-<i>Rag2</i> <sup><i>null</i></sup> <i>Il2rγ</i> <sup><i>null</i></sup> <i>Sirpα</i> <sup>NOD</sup>) neonates were engrafted with human CD34+ cells to generate HIS-BRGS mice.